<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03559439</url>
  </required_header>
  <id_info>
    <org_study_id>PTA001</org_study_id>
    <nct_id>NCT03559439</nct_id>
  </id_info>
  <brief_title>CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies</brief_title>
  <official_title>CD19-targeting CAR T Cell Therapy in the Treatment of Relapsed or Refractory CD19 Positive B-cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Tong Ren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gracell Biotechnology Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Tong Ren Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, single arm, open-label phase 1 study to determine the safety and
      efficacy of autologous T cells expressing CD19 chimeric antigen receptors in adults with
      CD19+ B cell malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, Open Label phase I clinical trial, 9 subjects planned to be
      enrolled. The subjects will be divided into low-dose group, medium-dose group and high-dose
      group.Dose CAR+ cells/kg Low 1×105 Medium 2×106 High 6×106
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 24, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of toxicities and adverse events</measure>
    <time_frame>24 weeks</time_frame>
    <description>To assess the frequency and severity of toxicities and adverse events according to NCI CTC v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>24 week</time_frame>
    <description>To assess the overall response rate after CD19 CAR T infusion in R/R B cell malignancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>24 week</time_frame>
    <description>To assess the overall survival in patients with R/R B cell malignancies</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>B-cell Malignancy</condition>
  <condition>B-cell Lymphoma</condition>
  <condition>B-Cell Acute Lymphoblastic Leukaemia</condition>
  <arm_group>
    <arm_group_label>CD19 CAR T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv CD3z:CD28 administered by IV infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD19 CAR T</intervention_name>
    <description>CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv CD3z:CD28 administered by IV infusion. Subjects will receive 0.1-10 x 10^6 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction, Day 2, 30% fraction, Day 3, 60% fraction.</description>
    <arm_group_label>CD19 CAR T</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. CD19+ relapsed or refractory B cell malignancies:

               -  Relapsed or refractory B acute lymphocytic leukemia.

                    -  Relapse was defined as presence of &gt; 5% blasts at screening, or second or
                       subsequent bone marrow relapse, or any bone marrow relapse after allogeneic
                       stem cell transplant and must be ≥ 6 months from stem cell transplant at the
                       time of infusion.

                    -  Refractory was defined by not achieving an initial complete response after 2
                       cycles of a standard chemotherapy regimen . Patients who were refractory to
                       subsequent chemotherapy regimens after an initial remission were considered
                       chemorefractory

               -  Patients with Ph+ acute lymphocytic leukemia were eligible if they are intolerant
                  to or have not achieved a remission after two lines of tyrosine kinase inhibitor
                  therapy, or if tyrosine kinase inhibitor therapy is contraindicated, or
                  ineligible for allogeneic stem cell transplant because of:

                    -  Comorbid disease

                    -  Other contraindications to allogeneic stem cell transplant conditioning
                       regimen

                    -  Lack of suitable donor

                    -  Prior hematopoietic stem cell transplant

                    -  Declined allogeneichematopoietic stem cell transplant as a therapeutic
                       option

               -  Relapsed or refractory non-Hodgkin's lymphoma

                    -  Histopathological CD19+.

                    -  No response to last line of therapy i. partial response as best response to
                       most recent therapy regimen ii. partial response as best response to most
                       recent therapy with duration no longer than 6 month from last dose of
                       therapy

                    -  Refractory post-Autologous stem cell transplant i. Disease progression or
                       relapsed less than or equal to 12 months of Autologous stem cell transplant
                       (must have biopsy proven recurrence in relapsed subjects) ii. If salvage
                       therapy is given post-Autologous stem cell transplant, the subject must have
                       had no response to or relapsed after the last line of therapy

                    -  Subjects must have received adequate prior therapy including at a minimum:
                       anti-CD20 monoclonal antibody unless investigator determines that tumor is
                       CD20-negative and an anthracycline containing chemotherapy regimen for
                       subjects with transformed follicular lymphoma must have received prior
                       chemotherapy for follicular lymphoma and subsequently have chemorefractory
                       disease after transformation to Diffuse large B-cell lymphoma

               -  At least one measurable lesion per revised IWG Response Criteria

          2. 18-75 years old

          3. Expected survival ≥ 12 weeks

          4. Adequate renal, hepatic, pulmonary and cardiac function defined as:

               -  Creatinine clearance (as estimated by Cockcroft Gault) &gt; 60 mL/min

               -  Serum ALT/AST &lt;2.5 ULN

               -  Total bilirubin &lt;1.5 mg/dl, except in subjects with Gilbert's syndrome

               -  Cardiac ejection fraction &gt;50%, no evidence of pericardial effusion as determined
                  by an echocardiogram, and no clinically significant pleural effusion

               -  Baseline oxygen saturation &gt;92% on room air

          5. Eastern cooperative oncology group (ECOG) performance status of 0 - 2

          6. Pregnant or lactating women must have a negative pregnancy test before infusion, and
             agree to take effective contraception during the trial

          7. Apheresis product received and accepted

          8. Written informed consent

        Exclusion Criteria:

          1. Isolated extra-medullary relapse leukemia

          2. Other malignancies

          3. Concomitant genetic syndrome, with the exception of Down Syndrome

          4. Burkitt's lymphoma/leukemia

          5. Treatment with any prior gene therapy product, anti-CD19/anti-CD3 therapy, or any
             other anti-CD19 therapy

          6. Active hepatitis B, C, or any uncontrolled infection

          7. Grade 2 to 4 Graft versus Host Disease (GVHD)

          8. Medications or treatments that were to be excluded:

               -  Corticosteroids within 72 hours of infusion, with the exception of physiologic
                  replacement

               -  Allogeneic cellular therapy, such as donor lymphocyte infusion within 6 weeks
                  prior to infusion

               -  Graft versus Host Disease therapies

               -  Chemotherapy stopped prior to lymphodepletion based on clearance

               -  central nervous system prophylaxis treatment

          9. Active central nervous system disease (central nervous system 2 disease [Cerebral
             spinal fluid containing blasts, but &lt; 5 WBCs/microliter] patients were eligible)

         10. Any condition that investigator considered may increase the risk of the subjects or
             interfere with the trial results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ligen Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Tong Ren Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ligen Liu</last_name>
    <phone>18017337037</phone>
    <email>llg3532@shtrhospital.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Tong Ren hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ligen Liu</last_name>
      <phone>18017337037</phone>
      <email>llg3532@shtrhospital.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 30, 2018</study_first_submitted>
  <study_first_submitted_qc>June 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>June 16, 2018</last_update_submitted>
  <last_update_submitted_qc>June 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Tong Ren Hospital</investigator_affiliation>
    <investigator_full_name>Liu Ligen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

